ReviewFrontiers in molecular biosciences2026
MBNL1-mediated alternative splicing in cancer: underlying mechanism, isoform regulation, and translational perspectives.
Review in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alternative splicing (AS) is a major mechanism that expands proteomic diversity and fine-tunes gene expression in eukaryotic cells. Its dysregulation is now recognized as a hallmark of cancer and contributes to tumor initiation, progression, metastasis, and therapeutic resistance. Muscleblind-like splicing regulator 1 (MBNL1) is a highly conserved RNA-binding protein (RBP) that controls AS, RNA stability, and other aspects of transcript processing. Increasing evidence indicates that MBNL1 expression, isoform composition, and subcellular localization are frequently altered in multiple cancer types. Through these changes, MBNL1 reshapes the splicing programs of cancer-related genes and exerts context-dependent tumor-suppressive or tumor-supportive effects. This review summarizes the structure and biological functions of MBNL1, the major mechanisms through which it regulates cancer-associated AS, its expression and isoform-specific features across different tumor types, and emerging therapeutic strategies targeting MBNL1 and its downstream splicing network. Current challenges and future directions are also discussed. Overall, MBNL1 represents a promising splicing regulator with potential value for biomarker development and precision cancer therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.